[go: up one dir, main page]

UA93209C2 - Комбинация снотворного агента продолжительного действия эпливансерина и снотворного агента короткого действия золпидема - Google Patents

Комбинация снотворного агента продолжительного действия эпливансерина и снотворного агента короткого действия золпидема

Info

Publication number
UA93209C2
UA93209C2 UAA200803488A UAA200803488A UA93209C2 UA 93209 C2 UA93209 C2 UA 93209C2 UA A200803488 A UAA200803488 A UA A200803488A UA A200803488 A UAA200803488 A UA A200803488A UA 93209 C2 UA93209 C2 UA 93209C2
Authority
UA
Ukraine
Prior art keywords
hypnotic agent
acting hypnotic
combination
short
long
Prior art date
Application number
UAA200803488A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ален Кюин
Мишель Декобер
Доминик Франкон
Анри Сональ
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of UA93209C2 publication Critical patent/UA93209C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение касается комбинации, по меньшей мере, одного снотворного агента короткого действия, который представляет собой золпидем, с по меньшей мере, одним снотворным агентом продолжительного действия, который представляет собой эпливансерин, и его применения для лечения расстройств сна.
UAA200803488A 2005-08-19 2006-07-27 Комбинация снотворного агента продолжительного действия эпливансерина и снотворного агента короткого действия золпидема UA93209C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508643A FR2889811B1 (fr) 2005-08-19 2005-08-19 Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.

Publications (1)

Publication Number Publication Date
UA93209C2 true UA93209C2 (ru) 2011-01-25

Family

ID=36273351

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200803488A UA93209C2 (ru) 2005-08-19 2006-07-27 Комбинация снотворного агента продолжительного действия эпливансерина и снотворного агента короткого действия золпидема

Country Status (25)

Country Link
US (2) US20080181943A1 (ru)
EP (1) EP1919473B1 (ru)
JP (1) JP5215851B2 (ru)
KR (1) KR20080039909A (ru)
CN (1) CN101267819B (ru)
AR (1) AR055123A1 (ru)
AU (1) AU2006281334B2 (ru)
BR (1) BRPI0614792A2 (ru)
CA (1) CA2618212C (ru)
CR (1) CR9695A (ru)
EA (1) EA014294B1 (ru)
EC (1) ECSP088131A (ru)
FR (1) FR2889811B1 (ru)
HN (1) HN2008000278A (ru)
IL (1) IL188823A0 (ru)
MA (1) MA29766B1 (ru)
MX (1) MX2008002275A (ru)
NO (1) NO20081250L (ru)
NZ (1) NZ565880A (ru)
SG (1) SG165316A1 (ru)
TN (1) TNSN08027A1 (ru)
TW (1) TW200738238A (ru)
UA (1) UA93209C2 (ru)
WO (1) WO2007020337A1 (ru)
ZA (1) ZA200800968B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
WO2009084023A2 (en) * 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
US20120108669A1 (en) * 2008-11-13 2012-05-03 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
FR2938534B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Procede de preparation de l'hemifumarate d'eplivanserine
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
JP5726766B2 (ja) 2009-02-13 2015-06-03 ロマーク ラボラトリーズ エル．シー． ニタゾキサニドの制御放出医薬配合物
EP2255726A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Spectral profile of SWS enhancing drugs
EP2255807A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Method of treating sleep disorders using the combination of eplivanserin and zolpidem
WO2012109695A1 (en) * 2011-02-16 2012-08-23 Casal Y Galzov Ramon Ernesto Drug compositions for the treatment of insomnia
US9700548B2 (en) 2011-06-09 2017-07-11 Requis Pharmaceuticals Inc. Antihistamines combined with dietary supplements for improved health
CN102579383A (zh) * 2012-04-09 2012-07-18 南京正科制药有限公司 右佐匹克隆缓释片
PT3102189T (pt) * 2014-02-06 2019-12-11 Bo Chen Lan Composição e método para melhorar o sono
CN108289849A (zh) 2015-06-26 2018-07-17 韩国联合制药株式会社 莫沙必利与雷贝拉唑的复合制剂
CN105596313B (zh) * 2016-02-17 2018-06-29 新乡医学院第一附属医院 一种具有反向药理功能的用于治疗失眠的胶囊制剂
CN105997958B (zh) * 2016-07-12 2019-03-26 中国人民解放军白求恩医务士官学校 一种口腔外用制剂及其制备方法
RS61024B1 (sr) * 2016-10-31 2020-12-31 Neurim Pharma 1991 Mini-tablete melatonina i postupak za njihovu proizvodnju
JP7053665B2 (ja) * 2016-12-30 2022-04-12 南京明徳新薬研発有限公司 Ｅｇｆｒ阻害としてのキナゾリン系化合物
CN118384147A (zh) 2018-01-30 2024-07-26 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
AU2019384157A1 (en) 2018-11-21 2021-06-17 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
CA3129270A1 (en) * 2019-02-08 2020-08-13 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
WO2021236876A2 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains
CN115919806A (zh) * 2022-12-22 2023-04-07 南京乐韬生物科技有限公司 一种gaba缓释胶囊的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4060599A (en) * 1998-06-09 1999-12-30 Takeda Chemical Industries Ltd. Pharmaceutical composition for treating or preventing sleep disorders
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
DK1691811T3 (da) * 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
CA2614244A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and an antidepressant
EP1937265A2 (en) * 2005-08-19 2008-07-02 Aventis Pharmaceuticals Inc. Comination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof
SG140147A1 (en) * 2005-08-19 2008-03-28 Aventis Pharma Inc Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof

Also Published As

Publication number Publication date
FR2889811A1 (fr) 2007-02-23
KR20080039909A (ko) 2008-05-07
EP1919473B1 (fr) 2012-12-05
JP5215851B2 (ja) 2013-06-19
HK1124541A1 (en) 2009-07-17
AU2006281334B2 (en) 2012-10-18
ECSP088131A (es) 2008-02-20
IL188823A0 (en) 2008-12-29
EA014294B1 (ru) 2010-10-29
AU2006281334A1 (en) 2007-02-22
CA2618212A1 (fr) 2007-02-22
CA2618212C (fr) 2014-03-25
FR2889811B1 (fr) 2009-10-09
WO2007020337A1 (fr) 2007-02-22
CN101267819B (zh) 2012-05-30
JP2009504713A (ja) 2009-02-05
EA200800618A1 (ru) 2008-06-30
AR055123A1 (es) 2007-08-08
MX2008002275A (es) 2008-03-27
ZA200800968B (en) 2009-04-29
HN2008000278A (es) 2011-03-30
MA29766B1 (fr) 2008-09-01
US20080181943A1 (en) 2008-07-31
NZ565880A (en) 2011-07-29
CR9695A (es) 2008-02-20
SG165316A1 (en) 2010-10-28
TNSN08027A1 (en) 2009-07-14
TW200738238A (en) 2007-10-16
CN101267819A (zh) 2008-09-17
US20100291204A1 (en) 2010-11-18
NO20081250L (no) 2008-05-13
EP1919473A1 (fr) 2008-05-14
BRPI0614792A2 (pt) 2011-04-12

Similar Documents

Publication Publication Date Title
TNSN08027A1 (en) Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
SV2005002148A (es) &#34;compuestos moduladores de la actividad c-kit y usos de los mismos&#34;
NZ548954A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
BRPI0418092A (pt) combinação terapêutica para melhora cognitiva e transtornos psicóticos
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
BR0104834A (pt) Moduladores de receptores de glucocorticóides
AU2003270199A1 (en) Urea compounds active as vanilloid receptor antagonists for the treatment of pain
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
DE60120077D1 (de) Modulatoren des Glucocorticoid-Rezeptors
MA32639B1 (fr) [4-(5-aminométhyl-2-fluoro-phényl)-pipéridin- 1-yl]-[7-fluoro-1- (2-méthoxy-éthyl)-4-trifluorométhoxy-1h-indol-3-yl]-méthanone en tant qu&#39;inhibiteur de la tryptase de mastocytes
ECSP067082A (es) Antagonistas de receptor de glucagon, preparacion y usos terapeuticos
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
UA83868C2 (ru) Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MX2007003545A (es) Composiciones y metodos para tratar trastornos cognitivos.
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
AU2003288858A1 (en) Use of cyclolignans as inhibitors of igf-1 receptor for treatment of malignat diseases
YU60803A (sh) Upotreba antagonista gal3 receptora u lečenju depresije i/ili uznemirenosti i jedinjenja korisna u tim postupcima